Darolutamide with Bipolar Androgen Therapy (BAT) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) – the DaroBAT Trial
(EU CT Number: 2025-521051-23-00)

Beteiligte Wissenschaftlerin:
Dr. rer. medic. M. Eveslage

Studienleitung:
Dr. med. Katrin Schlack

The goal of the DaroBAT trial is to compare the effects of bipolar androgen therapy (BAT) and Darolutamide vs. standard of care (e.g., Abiraterone, Cabazitaxel, Docetaxel, or Enzalutamide) in men with asymptomatic or mildly symptomatic castration-resistant prostate cancer who have only received one line of modern antihormonal treatment for the initial treatment of metastatic castration-sensitive prostate cancer. It is a prospective, multicenter, interventional, open-label, randomized, phase II trial.